8 research outputs found
Overall survival of the patients with B-NHL and controls.
<p>Overall survival of the patients with B-NHL and controls.</p
Predictive factors associated with sustained virologic response in the cohort treated by Peg-IFN-based therapy.
<p>Predictive factors associated with sustained virologic response in the cohort treated by Peg-IFN-based therapy.</p
Characteristics and follow-up of the patients with HCV infection and B-NHL treated by direct-acting antiviral drugs (DAAs).
<p>Marginal zone lymphomas (MZLs); Diffuse large B-cell lymphomas (DLBCLs).</p
Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.
<p>Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.</p
Sustained virologic response of the patients from the cohort treated by Peg-IFN-based therapy, * p< 0.02.
<p>First generation of protease inhibitors (PI1s). A: global sustained virologic response. B: sustained virologic response according to HCV genotype.</p
Safety in the cohort treated by Peg-IFN-based therapy.
<p>Safety in the cohort treated by Peg-IFN-based therapy.</p
Flowchart.
<p>Peg-interferon-alpha (Peg-IFN), B-cell non-Hodgkin lymphoma (B-NHL) First generation of protease inhibitors (PI1s), Direct-acting antiviral drugs (DAAs).</p
Characteristics of the patients treated by Peg-IFN-based therapy.
<p>Characteristics of the patients treated by Peg-IFN-based therapy.</p